肺癌与肺癌骨转移患者血清ODF、OCIF及Ca水平的研究
摘要
目的探讨联合检测破骨细胞分化因子(ODF)、破骨细胞生成抑制因子(OCIF)及血清钙(Ca)水平对肺癌骨转移诊断、疗效监测的临床价值。方法将114例经病理学确诊的肺癌患者,分为骨转移组63例,非骨转移组51例,采用酶联免疫吸附试验(ELISA)法对各组血清ODF和OCIF进行测定,偶氮砷Ⅲ法监测血清Ca水平。结果骨转移组血清ODF和OCIF分别为(30.25±5.43)、(37.33.±2.56)ng/L,明显高于非骨转移组[(7.13.±2.41)、(9.41±5.62)ng/L],差异有统计学意义(P<0.01)。骨转移组血清Ca为(3.31±0.43)mmol/L,高于非骨转移组[(2.25±0.32)mmol/L],差异有统计学意义(P<0.05)。骨转移组患者接受唑来膦酸治疗2、4个月的ODF、OCIF、Ca水平分别与治疗前比较,差异有统计学意义(P<0.05);6个月的ODF、OCIF、Ca水平分别与治疗前比较,差异有统计学意义(P<0.01)。结论肺癌患者发生骨转移时,血清ODF、OCIF及Ca水平明显升高,可作为肺癌骨转移患者的预测指标,对患者的治疗及疗效观察有广泛的应用前景。
引文
[1]韩雪,乔鹏,谢梦,等.2002-2010年上海市杨浦区居民肺癌发病与死亡分析[J].中华肿瘤杂志,2012,34(6):717.
[2]刘宇,张幸平,吴红宇,等.258例肺癌骨转移患者的临床及治疗相关因素分析[J].中国肿瘤临床,2012,39(13):914-918.
[3]RAFIEI S,KOMAROVA S V.Molecular signaling pathwavs mediating osteoclastogenesis Induced by prostate cancer cells[J].BMC Cancer,2013,26(13):605-607.
[4]KUSHLINSKIY N E,TIMOFEEVIU S,GERSHTEYN E S,et al.Clinical perspectives of the Study of RANK/RANKL/OPG system components in primary and metastatic bone tumor[J].Vopr Onkol,2014,60(4):413-421.
[5]HOFBAUEROF L C,KHOSLA S,DUNSTAN C R,et al.The rols of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].J Bone Miner Res,2000,15(1):2-12.
[6]WALSH M C,CHOI Y.Bioiogy of the TRANCE axis[J].Cytokine Growth Factor Rew,2003,14(3/4):251-263.
[7]KOIDE M,MURASE Y,YAMATO K,et al.Bone morphogenetie protein-2enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2[J].Biochem Biophys Res Commun,1999,259(1):97-102.
[8]赵雪志,李纲,王振杰,等.前列腺癌患者血清骨保护素测定的临床价值[J].中国综合临床,2010,26(12):1242-1243.
[9]谭云昌.血清破骨细胞分化因子及生成抑制因子测定在前列腺癌骨转移诊断中的价值[J].中国现代医学杂志,2014,23(1):37-40.
[10]GUPTA D,TRUKOVA K,POPIEL B,et al.The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stageⅣprostate cancer[J].PLoS One,2015,10(3):e0119690.
[11]SOYFOO M S,BRENNER K,Paesmans M,et al.Nonmalignant causes of hypercalcemia in cancer patients:a frequent and neglected occurrence[J].Support Care Cancer,2013,21(5):1415-1419.
[12]SKERJANEC A,BERENSON J,HSU C,et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
[13]BODY J J,LORTHOLARY A,ROMIEU G,et al.A dose-finding study of zoledronate inhypercalcemic cancer patients[J].J Bone Miner Res,2009,14(9):1557-1561.
[14]COLEMAN R,GNANT M.New results from the use of bisphosphonates in cancer patients[J].Curr Opin Support Palliat Care,2009,3(3):213-218.
[15]COSTA L,MAJOR P P.Effect of bisphosphonates on pain and quality of life in patients with bone metastases[J].Nat Clin Pract Oncol,2009,6(3):163-17
[16]KELLER J,CATALA-LEHNEN P,HUEBNER A K,et al.Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate fromosteoclasts[J].Nat Commun,2014,59(4):12-15.
[17]赵晓亮.唑来膦酸与帕米膦酸二钠治疗肺癌骨转移疼痛的疗效与安全性对比分析[J].现代预防医学,2011,38(6):1179-1180.
[2]刘宇,张幸平,吴红宇,等.258例肺癌骨转移患者的临床及治疗相关因素分析[J].中国肿瘤临床,2012,39(13):914-918.
[3]RAFIEI S,KOMAROVA S V.Molecular signaling pathwavs mediating osteoclastogenesis Induced by prostate cancer cells[J].BMC Cancer,2013,26(13):605-607.
[4]KUSHLINSKIY N E,TIMOFEEVIU S,GERSHTEYN E S,et al.Clinical perspectives of the Study of RANK/RANKL/OPG system components in primary and metastatic bone tumor[J].Vopr Onkol,2014,60(4):413-421.
[5]HOFBAUEROF L C,KHOSLA S,DUNSTAN C R,et al.The rols of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].J Bone Miner Res,2000,15(1):2-12.
[6]WALSH M C,CHOI Y.Bioiogy of the TRANCE axis[J].Cytokine Growth Factor Rew,2003,14(3/4):251-263.
[7]KOIDE M,MURASE Y,YAMATO K,et al.Bone morphogenetie protein-2enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2[J].Biochem Biophys Res Commun,1999,259(1):97-102.
[8]赵雪志,李纲,王振杰,等.前列腺癌患者血清骨保护素测定的临床价值[J].中国综合临床,2010,26(12):1242-1243.
[9]谭云昌.血清破骨细胞分化因子及生成抑制因子测定在前列腺癌骨转移诊断中的价值[J].中国现代医学杂志,2014,23(1):37-40.
[10]GUPTA D,TRUKOVA K,POPIEL B,et al.The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stageⅣprostate cancer[J].PLoS One,2015,10(3):e0119690.
[11]SOYFOO M S,BRENNER K,Paesmans M,et al.Nonmalignant causes of hypercalcemia in cancer patients:a frequent and neglected occurrence[J].Support Care Cancer,2013,21(5):1415-1419.
[12]SKERJANEC A,BERENSON J,HSU C,et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
[13]BODY J J,LORTHOLARY A,ROMIEU G,et al.A dose-finding study of zoledronate inhypercalcemic cancer patients[J].J Bone Miner Res,2009,14(9):1557-1561.
[14]COLEMAN R,GNANT M.New results from the use of bisphosphonates in cancer patients[J].Curr Opin Support Palliat Care,2009,3(3):213-218.
[15]COSTA L,MAJOR P P.Effect of bisphosphonates on pain and quality of life in patients with bone metastases[J].Nat Clin Pract Oncol,2009,6(3):163-17
[16]KELLER J,CATALA-LEHNEN P,HUEBNER A K,et al.Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate fromosteoclasts[J].Nat Commun,2014,59(4):12-15.
[17]赵晓亮.唑来膦酸与帕米膦酸二钠治疗肺癌骨转移疼痛的疗效与安全性对比分析[J].现代预防医学,2011,38(6):1179-1180.